Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07617493 | Evaluation of ICP-B208 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 539 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07695142 | A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 275 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 10, 2026 |
| clinicaltrials |
| NCT06625593 | A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 168 | BeOne MedicinesINDUSTRY | 4 | Jul 9, 2026 | clinicaltrials |
| NCT06874335 | A Phase 1 Study of BHV-1530 in Advanced Solid Tumors | recruiting | Phase 1 | 140 | Biohaven Therapeutics Ltd.INDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07691775 | A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | Heron Neutron Medical Corp.INDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT02112565 | RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists | active not recruiting | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT02650986 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | active not recruiting | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04328844 | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | active not recruiting | Phase 1 | 210 | iOncturaINDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT06320405 | Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 38 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06888830 | A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour | recruiting | Phase 1 / Phase 2 | 374 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05768139 | First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors(PIKALO-1) | recruiting | Phase 1 / Phase 2 | 880 | Eli Lilly and CompanyINDUSTRY | 9 | Jul 7, 2026 | clinicaltrials |
| NCT06571422 | Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors | active not recruiting | Phase 1 | 59 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 2 | Jul 7, 2026 | clinicaltrials |
| NCT07337525 | A First in Human Study of PLT012 in Participants With Solid Tumor Cancers | recruiting | Phase 1 | 36 | Pilatus Biosciences IncINDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07688577 | XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 140 | Xilio Development, Inc.INDUSTRY | 0 | Jul 7, 2026 | clinicaltrials |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | recruiting | Phase 1 / Phase 2 | 370 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT05887492 | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 126 | Tango Therapeutics, Inc.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06043713 | Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations | recruiting | Phase 1 | 24 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06239467 | First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer(PIKture-01) | active not recruiting | Phase 1 | 200 | OnKure, Inc.INDUSTRY | 6 | Jul 6, 2026 | clinicaltrials |
| NCT07300150 | A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors | recruiting | Phase 1 | 210 | PAQ Therapeutics, Inc.INDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT04626635 | A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers(COMBINE-EGFR-1) | active not recruiting | Phase 1 / Phase 2 | 548 | Regeneron PharmaceuticalsINDUSTRY | 7 | Jul 2, 2026 | clinicaltrials |
| NCT06166836 | a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 140 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07682337 | Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects | not yet recruiting | Phase 1 | 74 | SCBIO Inc.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07664150 | CW-301 FIH Study of CAN016 | recruiting | Phase 1 / Phase 2 | 90 | Canwell Biotech LimitedINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05170958 | A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 / Phase 2 | 396 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05720117 | A Study of PYX-201 in Advanced Solid Tumors | recruiting | Phase 1 | 330 | Pyxis Oncology, IncINDUSTRY | 4 | Jun 30, 2026 | clinicaltrials |
| NCT07140393 | A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor | recruiting | Phase 1 / Phase 2 | 120 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07508761 | IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 52 | Nanjing Immunophage Biotech Co., LtdINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05861895 | HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors | recruiting | Phase 1 | 84 | HighField Biopharmaceuticals CorporationINDUSTRY | 2 | Jun 26, 2026 | clinicaltrials |
| NCT07606612 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 31 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07665970 | SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 112 | Sinocelltech Ltd.INDUSTRY | 0 | Jun 26, 2026 | clinicaltrials |
| NCT04219254 | A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 197 | BioInvent International ABINDUSTRY | 7 | Jun 25, 2026 | clinicaltrials |
| NCT05672459 | A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06220864 | SNV1521 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 400 | Synnovation Therapeutics, Inc.INDUSTRY | 7 | Jun 25, 2026 | clinicaltrials |
| NCT06352359 | Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors | recruiting | Phase 1 | 72 | OncoC4, Inc.INDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06394414 | A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors | active not recruiting | Phase 1 | 187 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06431594 | A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1) | recruiting | Phase 1 | 675 | GlaxoSmithKlineINDUSTRY | 15 | Jun 25, 2026 | clinicaltrials |
| NCT06952010 | A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 303 | ExelixisINDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07060989 | A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation(NTS071) | recruiting | Phase 1 / Phase 2 | 220 | Nutshell Therapeutics (Shanghai) Co., LTD.INDUSTRY | 2 | Jun 24, 2026 | clinicaltrials |
| NCT07664397 | Imaging Study of [89Zr]DFO-YS5 for Cancer Detection | not yet recruiting | Phase 1 | 40 | Robert Flavell, MD, PhDOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 138 | Toray Industries, IncINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT04678648 | A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies | recruiting | Phase 1 | 134 | RasCal Therapeutics, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05584670 | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | SanofiINDUSTRY | 6 | Jun 23, 2026 | clinicaltrials |
| NCT05684965 | XTX301 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 358 | Xilio Development, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06993844 | Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 233 | Ensem TherapeuticsINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT05143970 | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors(CHANCES) | active not recruiting | Phase 1 | 27 | Institut Paoli-CalmettesOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05434234 | A Study of YL201 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 312 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 6 | Jun 22, 2026 | clinicaltrials |
| NCT07658677 | Cannabis Gummy for the Improvement of Sleep and Quality of Life in Patients With Cancer, Pillow Trial | not yet recruiting | Phase 1 / Phase 2 | 50 | Theodore Brasky PhDOTHER | 1 | Jun 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 10, 2026source: clinicaltrials